PL3870579T3 - Inhibitory tyk2 i ich zastosowania - Google Patents

Inhibitory tyk2 i ich zastosowania

Info

Publication number
PL3870579T3
PL3870579T3 PL19877015.8T PL19877015T PL3870579T3 PL 3870579 T3 PL3870579 T3 PL 3870579T3 PL 19877015 T PL19877015 T PL 19877015T PL 3870579 T3 PL3870579 T3 PL 3870579T3
Authority
PL
Poland
Prior art keywords
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
PL19877015.8T
Other languages
English (en)
Inventor
Bohan Jin
Qing Dong
Gene Hung
Stephen W. Kaldor
Original Assignee
Alumis Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc. filed Critical Alumis Inc.
Publication of PL3870579T3 publication Critical patent/PL3870579T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19877015.8T 2018-10-22 2019-10-22 Inhibitory tyk2 i ich zastosowania PL3870579T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862749003P 2018-10-22 2018-10-22
US201862756942P 2018-11-07 2018-11-07
US201962839459P 2019-04-26 2019-04-26
US201962875449P 2019-07-17 2019-07-17
US201962893721P 2019-08-29 2019-08-29
US201962907354P 2019-09-27 2019-09-27
PCT/US2019/057485 WO2020086616A1 (en) 2018-10-22 2019-10-22 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
PL3870579T3 true PL3870579T3 (pl) 2025-03-17

Family

ID=70330735

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19877015.8T PL3870579T3 (pl) 2018-10-22 2019-10-22 Inhibitory tyk2 i ich zastosowania

Country Status (25)

Country Link
US (5) US11053219B2 (pl)
EP (3) EP4461734B1 (pl)
JP (2) JP7631193B2 (pl)
KR (1) KR102850357B1 (pl)
CN (1) CN113490664B (pl)
AU (1) AU2019364336B2 (pl)
BR (1) BR112021007679A2 (pl)
CA (1) CA3117200A1 (pl)
CL (1) CL2021000989A1 (pl)
DK (1) DK3870579T3 (pl)
ES (1) ES3011855T3 (pl)
FI (1) FI3870579T3 (pl)
HR (1) HRP20250048T1 (pl)
HU (1) HUE070644T2 (pl)
IL (1) IL282487A (pl)
LT (1) LT3870579T (pl)
MX (1) MX2021004538A (pl)
PL (1) PL3870579T3 (pl)
PT (1) PT3870579T (pl)
RS (1) RS66346B1 (pl)
SA (1) SA521421806B1 (pl)
SG (1) SG11202104017VA (pl)
SI (1) SI3870579T1 (pl)
SM (1) SMT202500070T1 (pl)
WO (1) WO2020086616A1 (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104017VA (en) * 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
EA202192134A1 (ru) * 2019-01-30 2021-11-03 Бристол-Маерс Сквибб Компани Амидзамещенные гетероциклические соединения
ES2987809T3 (es) * 2019-03-05 2024-11-18 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa
CN114127073B (zh) 2019-07-16 2024-05-31 密歇根大学董事会 作为eed抑制剂的咪唑并嘧啶和其用途
KR20220034853A (ko) * 2019-07-16 2022-03-18 브리스톨-마이어스 스큅 컴퍼니 인터류킨의 조정에서의 전구약물
IL291413B2 (en) 2019-09-27 2025-03-01 Takeda Pharmaceuticals Co 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
SMT202400185T1 (it) * 2020-03-11 2024-07-09 Beijing Innocare Pharma Tech Co Ltd Composti eterociclici per inibire attività di tyk2
TW202204344A (zh) * 2020-04-01 2022-02-01 美商永恒生物科技公司 酪胺酸激酶2抑制劑、其製備方法及醫藥用途
JP2023522195A (ja) * 2020-04-14 2023-05-29 ゴッサマー バイオ サービシズ、インコーポレイテッド 炎症性疾患の治療のための置換ピリジン
CN113563309B (zh) * 2020-04-28 2024-12-13 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
WO2021259208A1 (en) * 2020-06-22 2021-12-30 Beigene, Ltd. Tyk-2 inhibitor
CN114057651B (zh) * 2020-07-31 2025-05-27 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
WO2022032484A1 (zh) * 2020-08-11 2022-02-17 北京诺诚健华医药科技有限公司 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
US20230339977A1 (en) * 2020-08-13 2023-10-26 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and application thereof
CN114075220A (zh) * 2020-08-13 2022-02-22 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2022105771A1 (zh) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用
CA3203014A1 (en) * 2020-12-02 2022-06-09 Shenzhen Chipscreen Biosciences Co., Ltd. Hydroxamate compound, preparation method therefor and application thereof
WO2022121868A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
CN115160297B (zh) * 2020-12-22 2023-03-31 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
WO2022175747A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
TW202246232A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
WO2022179578A1 (zh) * 2021-02-24 2022-09-01 南京明德新药研发有限公司 含有亚磺酰基吡啶结构的化合物以及应用
CN112920103A (zh) * 2021-03-02 2021-06-08 康化（上海）新药研发有限公司 一种温和制备2-氮杂螺[3.3]庚烷盐酸盐的方法
WO2022193499A1 (en) 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
CN116888125B (zh) * 2021-04-07 2024-04-12 上海齐鲁制药研究中心有限公司 Tyk2抑制剂及其用途
KR20240016974A (ko) * 2021-05-04 2024-02-06 상하이 즈헤예 바이오테크놀로지 씨오. 엘티디. 질소-함유 헤테로시클릭 피리딘 화합물
US20250066322A1 (en) * 2021-05-14 2025-02-27 Bristol-Myers Squibb Company Substituted heterocyclic compounds
MX2023013351A (es) 2021-05-14 2023-11-27 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos.
WO2022253333A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 酰胺类化合物及其应用
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
CN115466289A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用
JP2024526156A (ja) * 2021-06-22 2024-07-17 メッドシャイン ディスカバリー インコーポレイテッド スルホキシイミン化合物およびその使用
US20240335462A1 (en) * 2021-07-15 2024-10-10 Medshine Discovery Inc. Sulfur/phosphorus-containing aryl compound and application thereof
CN118159338A (zh) 2021-08-10 2024-06-07 奇特实验室有限责任公司 用于毛发治疗的组合物、制剂和方法
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
US20240425456A1 (en) * 2021-09-30 2024-12-26 Aska Pharmaceutical Co., Ltd. Degrader
WO2023064223A1 (en) * 2021-10-11 2023-04-20 Gossamer Bio Services, Inc. Tri-substituted pyridines
MX2024004993A (es) 2021-10-25 2024-05-07 Kymera Therapeutics Inc Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Ｔｙｋ２抑制劑及其組合物和方法
KR20240127973A (ko) * 2021-12-23 2024-08-23 베이진 스위찰랜드 게엠베하 Tyk2 억제제의 고체 형태, 제조 방법, 및 이의 용도
WO2023116748A1 (zh) * 2021-12-23 2023-06-29 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN116693449A (zh) * 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
AU2023245329A1 (en) 2022-03-29 2024-10-10 Alumis Inc. Tyk2 inhibitors and uses thereof
EP4522602A1 (en) * 2022-05-13 2025-03-19 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof
CN117186075A (zh) * 2022-06-07 2023-12-08 广州费米子科技有限责任公司 取代的哒嗪-3-甲酰胺化合物作为tyk2抑制剂
TW202348226A (zh) * 2022-06-07 2023-12-16 大陸商廣州費米子科技有限責任公司 噠嗪-3-甲醯胺化合物作為tyk2抑制劑
CN117263913A (zh) * 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
CN117257752A (zh) * 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 药物组合物及其用途
EP4587431A1 (en) * 2022-09-12 2025-07-23 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
US12251459B2 (en) 2022-10-12 2025-03-18 Oddity Labs, Llc Compositions, formulations, and methods for hair treatment
KR20250099236A (ko) * 2022-11-08 2025-07-01 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
WO2024123668A1 (en) * 2022-12-05 2024-06-13 Oddity Labs, Llc Compositions, formulations, and methods for hair treatment
TW202430168A (zh) 2022-12-16 2024-08-01 印度商阿蘭比克製藥有限公司 Tyk2假激酶配體及其用途
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
WO2024173764A1 (en) 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa
WO2024257023A1 (en) * 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
TW202527949A (zh) 2023-09-20 2025-07-16 美商雅盧米斯公司 Tyk2抑制劑之立即釋放調配物
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025194074A1 (en) * 2024-03-15 2025-09-18 Neuron23, Inc. Kinase modulators and methods of use thereof
WO2025240835A2 (en) * 2024-05-17 2025-11-20 Prelude Therapeutics Incorporated Jak2 inhibitors and their use as pharmaceuticals
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof
WO2026019900A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US20060281763A1 (en) 2005-03-25 2006-12-14 Axon Jonathan R Carboxamide inhibitors of TGFbeta
US7517882B2 (en) 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
KR101773313B1 (ko) 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
TWI484961B (zh) 2009-05-08 2015-05-21 Astellas Pharma Inc Diamine heterocyclic methyl ester compounds
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
EP2975027A1 (en) * 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
TW201238938A (en) 2010-11-01 2012-10-01 Portola Pharm Inc Benzamides and nicotinamides as Syk modulators
CN102250065B (zh) 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
PT2760453T (pt) 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2
CA2860547A1 (en) * 2012-01-10 2013-07-18 Johannes Cornelius Hermann Pyridazine amide compounds and their use as syk inhibitors
CA2890981C (en) * 2012-11-08 2022-07-05 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
CN104995173A (zh) 2012-11-30 2015-10-21 协和发酵麒麟株式会社 含氮杂环化合物
AU2014230111A1 (en) 2013-03-15 2015-10-29 Oncodesign S.A Macrocyclic RIP2 kinase inhibitors
AU2014312756B2 (en) 2013-08-29 2018-11-22 Kyoto Pharmaceutical Industries, Ltd. Novel aromatic compound and use thereof
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
CA2932609A1 (en) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX2016009588A (es) 2014-01-24 2017-05-15 Tp Therapeutics Inc Macrociclos de diarilo como moduladores de la proteina quinasa.
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
CN105111151B (zh) 2015-04-17 2018-09-28 成都理工大学 作为PPAR-γ调节剂的氨基嘧啶衍生物
AU2016270907B2 (en) * 2015-06-02 2020-09-17 Pharmacyclics Llc. Inhibitors of Bruton's tyrosine kinase
CN107735399B (zh) 2015-07-02 2021-01-26 特普医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP6843135B2 (ja) 2015-11-18 2021-03-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
JP6916796B2 (ja) 2016-01-22 2021-08-11 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体
CN109715165A (zh) 2016-07-28 2019-05-03 Tp生物医药公司 巨环激酶抑制剂
MA46453A (fr) 2016-10-07 2019-08-14 Bristol Myers Squibb Co Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018112027A1 (en) 2016-12-14 2018-06-21 Development Center For Biotechnology Antibody-drug conjugates and uses thereof
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN106866660B (zh) 2017-02-15 2019-05-17 上海天马有机发光显示技术有限公司 电子传输材料、包含其的oled显示面板和电子设备
AU2018230737B2 (en) 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3607944A4 (en) * 2017-04-03 2020-11-18 Kyoto Pharmaceutical Industries, Ltd. NEW INHIBITOR OF THE CYCLINE-DEPENDENT KINASE 8 AND / OR 19
WO2018234345A1 (en) 2017-06-21 2018-12-27 F. Hoffmann-La Roche Ag PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
PL3674307T3 (pl) 2017-08-23 2023-11-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Związek makrocykliczny zawierający ugrupowanie aminopirazolu i pirymidyny oraz kompozycja farmaceutyczna i i ch zastosowanie
JPWO2019049891A1 (ja) 2017-09-06 2020-10-15 小野薬品工業株式会社 Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
US11065243B2 (en) 2017-10-27 2021-07-20 Sonic Master Limited Inhibitors of DUX4 induction for regulation of muscle function
US11098046B2 (en) 2017-11-10 2021-08-24 Angex Pharmaceutical, Inc. Macrocyclic compounds as TRK kinase inhibitors and uses thereof
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
CN111848622A (zh) 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
US11464780B2 (en) 2018-02-28 2022-10-11 Simcere Pharmaceutical Co. Ltd. Pyrazolopyrimidine derivative and use thereof
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN109053682B (zh) 2018-07-27 2020-10-27 东南大学 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法
SG11202104017VA (en) * 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
JP7699052B2 (ja) 2019-01-23 2025-06-26 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
CN115448910B (zh) 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN113677347A (zh) 2019-02-07 2021-11-19 温缇克斯生物科学公司 Tyk2假激酶配体
CN113811534B (zh) 2019-03-11 2024-10-29 阿鲁米斯公司 Tyk2抑制剂和其用途
JP7595582B2 (ja) 2019-03-26 2024-12-06 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
US11753411B2 (en) 2019-11-08 2023-09-12 Ventyx Biosciences, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands

Also Published As

Publication number Publication date
JP7631193B2 (ja) 2025-02-18
CN113490664A (zh) 2021-10-08
RS66346B1 (sr) 2025-01-31
EP4480953A2 (en) 2024-12-25
DK3870579T3 (da) 2025-01-02
EP4461734A2 (en) 2024-11-13
SA521421806B1 (ar) 2024-11-20
AU2019364336A1 (en) 2021-05-27
HRP20250048T1 (hr) 2025-03-28
WO2020086616A1 (en) 2020-04-30
EP3870579A1 (en) 2021-09-01
CA3117200A1 (en) 2020-04-30
US20230021554A1 (en) 2023-01-26
SG11202104017VA (en) 2021-05-28
US12006306B2 (en) 2024-06-11
EP3870579B1 (en) 2024-10-02
US20220235035A1 (en) 2022-07-28
PT3870579T (pt) 2025-01-27
IL282487A (en) 2021-06-30
US20230023761A1 (en) 2023-01-26
EP4461734A3 (en) 2024-12-11
CN113490664B (zh) 2025-05-16
US20230391751A1 (en) 2023-12-07
EP4461734B1 (en) 2026-02-04
FI3870579T3 (fi) 2025-01-02
US11053219B2 (en) 2021-07-06
CL2021000989A1 (es) 2021-10-29
JP2022505987A (ja) 2022-01-14
ES3011855T3 (en) 2025-04-08
KR20210095634A (ko) 2021-08-02
US11731956B2 (en) 2023-08-22
HUE070644T2 (hu) 2025-06-28
EP4480953A3 (en) 2025-02-19
JP2025090577A (ja) 2025-06-17
KR102850357B1 (ko) 2025-08-27
BR112021007679A2 (pt) 2021-07-27
SMT202500070T1 (it) 2025-03-12
EP4480953B1 (en) 2026-02-04
SI3870579T1 (sl) 2025-03-31
US20200354338A1 (en) 2020-11-12
LT3870579T (lt) 2025-01-27
AU2019364336B2 (en) 2023-11-16
MX2021004538A (es) 2021-09-10
EP3870579A4 (en) 2022-10-19
US12351572B2 (en) 2025-07-08
US12060343B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
SG11202104017VA (en) Tyk2 inhibitors and uses thereof
IL324623A (en) Tyk2 inhibitors and their uses
IL271999A (en) TYK2 inhibitors and uses thereof
IL283409A (en) tyk2 inhibitors and uses thereof
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL276147A (en) GCN2 inhibitors and uses thereof
IL276095B1 (en) gcn2 inhibitors and their uses
IL282350A (en) Bernani-RGMC inhibitors and their use
IL277794A (en) ATF6 inhibitors and uses thereof
EP3344624B8 (en) Tyk2 inhibitors and uses thereof
IL272649A (en) AHR inhibitors and their uses
EP3262049A4 (en) Tyk2 inhibitors and uses thereof
IL284799A (en) Tyk2 inhibitors and uses thereof
SG10201913927VA (en) Kinase inhibitors and uses thereof
SMT202300256T1 (it) Inibitori di lrrc33 e loro uso
IL291217A (en) usp30 inhibitors and their uses
IL292198A (en) Tim-3 inhibitors and their uses
HK40060743A (en) Tyk2 inhibitors and uses thereof
HK40059512A (en) Tyk2 inhibitors and uses thereof
GB201908884D0 (en) Inhibitors and use
HK40063694A (en) Tyk2 inhibitors and uses thereof
HK40012789A (en) Tyk2 inhibitors and uses thereof